Patent: 10,059,762
✉ Email this page to a colleague
Summary for Patent: 10,059,762
| Title: | Anti-EGFR activatable antibodies |
| Abstract: | The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies. |
| Inventor(s): | Stagliano; Nancy Elizabeth (San Francisco, CA), West; James William (Bend, OR), Kamath; Kathryn (Santa Barbara, CA), Bessette; Paul Henry (San Francisco, CA), Gluck; Fred (Santa Barbara, CA), Sagert; Jason Gary (San Mateo, CA), Daugherty; Patrick (Santa Barbara, CA) |
| Assignee: | CytomX Therapeutics, Inc. (South San Francisco, CA) |
| Application Number: | 15/140,944 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,059,762
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Microbix Biosystems Inc. | KINLYTIC | urokinase | For Injection | 021846 | 01/16/1978 | ⤷ Try a Trial | 2029-01-12 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2029-01-12 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2029-01-12 |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2029-01-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
